Emcure Pharmaceuticals has announced it will host an earnings call to discuss its unaudited financial results for the quarter ended June 30, 2026. The conference call is scheduled for Thursday, August 6, 2026, at 4:00 PM IST and will cover the company's standalone and consolidated performance for Q1 FY27.

The management team will conduct the session via Zoom Webinar, beginning with brief remarks followed by a question-and-answer session for analysts and investors. The disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Participants are required to register in advance to join the call, and the company has advised attendees to join the webinar 10 minutes prior to the scheduled start time to ensure a smooth connection.

Conference Call Details

Post-Call Disclosures

Following the conclusion of the earnings call, Emcure Pharmaceuticals will make an audio recording available before the next trading day or within 24 hours from the end of the call, whichever is earlier. A full transcript of the proceedings will be published within five working days. Both the audio recording and the transcript will be accessible on the company's official website, www.emcure.com , under the Investors section. Institutional investors with queries may contact Saurabh Paliwal via email at investor.relations@emcure.com .

Emcure Pharmaceuticals has executed Share Transfer Agreements to acquire 663,865 equity shares, constituting 12.05% of the total issued and paid-up capital of Gennova Biopharmaceuticals Limited. The acquisition is valued at an aggregate cash consideration of ₹231.87 Crore (₹2,318.7 Million), and will make Gennova a wholly-owned subsidiary upon completion. Emcure is acquiring the entire 12.05% minority stake held by Dr. Sanjay Singh and others, taking its ownership from 87.95% to 100%. The transaction is scheduled to be finalized on or before July 31, 2026.

Gennova, currently a subsidiary of Emcure, is involved in the research and development, manufacturing, and marketing of biotechnology-based products. The company's paid-up share capital stands at ₹55,113,650, and it was incorporated on June 19, 2001, operating exclusively in India. Post-acquisition, Gennova will be led by Mr. Samit Mehta and will continue to focus on its biologics franchise — Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX® and Hamsyl® — biosimilars development, and adjacent therapeutic platforms.

Financial Particulars of Gennova Biopharmaceuticals

For the financial year ended March 31, 2026, Gennova reported a turnover of ₹4,917.42 Million and a Profit After Tax (PAT) of ₹54.25 Million. The table below presents a summary of Gennova's recent financial performance alongside key transaction details.

Transaction Structure and Regulatory Details

The acquisition involves purchasing shares from individual shareholders, including relatives of a Promoter and Director of Emcure who are members of Gennova. As the target entity is a related party, the transaction is being undertaken at arm's length. No governmental or regulatory approvals are required for the deal. The transaction is not expected to have a material impact on Emcure's consolidated financials or its capital allocation framework, and the company's deleveraging trajectory, capex plans, and R&D investment plans remain unchanged.